Bank of America Corp DE Decreases Holdings in Genmab A/S (NASDAQ:GMAB)
Bank of America Corp DE Decreases Holdings in Genmab A/S (NASDAQ:GMAB)
Bank of America Corp DE trimmed its holdings in shares of Genmab A/S (NASDAQ:GMAB – Get Rating) by 1.3% in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 850,120 shares of the company's stock after selling 11,121 shares during the period. Bank of America Corp DE owned 0.13% of Genmab A/S worth $30,757,000 as of its most recent filing with the Securities and Exchange Commission.
美国银行DE在最近提交给美国证券交易委员会的文件中称，该公司第一季度减持了1.3%的Genmab A/S(纳斯达克代码：GMAB-GET)股票。该公司在此期间出售了11,121股后，拥有850,120股该公司的股票。截至最近提交给美国证券交易委员会(Securities And Exchange Commission)的文件，美国银行DE拥有Genmab A/S 0.13%的股份，价值30,757,000美元。
A number of other institutional investors have also recently added to or reduced their stakes in the business. Captrust Financial Advisors boosted its position in Genmab A/S by 62.0% in the 1st quarter. Captrust Financial Advisors now owns 2,658 shares of the company's stock valued at $96,000 after buying an additional 1,017 shares during the last quarter. Sentinel Trust Co. LBA purchased a new position in Genmab A/S in the 4th quarter valued at about $219,000. Seven Eight Capital LP purchased a new position in Genmab A/S in the 1st quarter valued at about $215,000. SG Americas Securities LLC boosted its position in Genmab A/S by 9.3% in the 1st quarter. SG Americas Securities LLC now owns 6,050 shares of the company's stock valued at $219,000 after buying an additional 513 shares during the last quarter. Finally, Wrapmanager Inc. boosted its position in Genmab A/S by 30.7% in the 1st quarter. Wrapmanager Inc. now owns 6,757 shares of the company's stock valued at $244,000 after buying an additional 1,589 shares during the last quarter. 5.51% of the stock is owned by hedge funds and other institutional investors.
其他一些机构投资者最近也增持或减持了该公司的股份。CapTrust Financial Advisors在第一季度将其在Genmab A/S的头寸提高了62.0%。CapTrust Financial Advisors现在持有该公司2,658股股票，价值96,000美元，此前在上个季度又购买了1,017股。Sentinel Trust Co.LBA在第四季度购买了Genmab A/S的一个新头寸，价值约21.9万美元。SEVEN Eight Capital LP在第一季度购买了Genmab A/S的一个新头寸，价值约215,000美元。SG America Securities LLC在第一季度将其在Genmab A/S的头寸提高了9.3%。SG America Securities LLC现在持有该公司6,050股股票，价值21.9万美元，上个季度又购买了513股。最后，WrapManager Inc.在第一季度将其在Genmab A/S的头寸提高了30.7%。在上个季度又购买了1,589股后，WrapManager Inc.现在持有6,757股该公司股票，价值24.4万美元。5.51%的股票由对冲基金和其他机构投资者持有。
Wall Street Analyst Weigh In
华尔街分析师也加入进来
A number of research firms have weighed in on GMAB. BMO Capital Markets began coverage on shares of Genmab A/S in a research report on Thursday, June 23rd. They issued a "market perform" rating and a $34.73 price objective for the company. TheStreet upgraded shares of Genmab A/S from a "c+" rating to a "b" rating in a research note on Wednesday, August 31st. HC Wainwright upped their target price on shares of Genmab A/S from $49.00 to $51.00 and gave the company a "buy" rating in a research note on Monday, August 22nd. Morgan Stanley upped their target price on shares of Genmab A/S from $29.00 to $31.00 and gave the company an "underweight" rating in a research note on Monday, August 15th. Finally, SVB Leerink upped their target price on shares of Genmab A/S from $30.00 to $31.00 and gave the company a "market perform" rating in a research note on Thursday, August 11th. One research analyst has rated the stock with a sell rating, seven have issued a hold rating and two have assigned a buy rating to the company. According to MarketBeat, the company presently has an average rating of "Hold" and an average price target of $547.62.
一些研究公司已经对GMAB发表了看法。蒙特利尔银行资本市场在6月23日星期四的一份研究报告中开始报道Genmab A/S的股票。他们给出了“市场表现”的评级和34.73美元的公司目标价。华尔街在8月31日星期三的一份研究报告中将Genmab A/S的股票评级从“c+”上调至“b”。8月22日，周一，HC Wainwright在一份研究报告中将Genmab A/S的目标价从49.00美元上调至51.00美元，并给予该公司“买入”评级。8月15日，周一，摩根士丹利在一份研究报告中将Genmab A/S的目标价从29.00美元上调至31.00美元，并给予该公司“减持”评级。最后，SVB Leerink在8月11日(星期四)的一份研究报告中将Genmab A/S的目标价从30.00美元上调至31.00美元，并给出了该公司的市场表现评级。一位研究分析师将该股的评级定为卖出，7位分析师给出了持有评级，两位分析师给出了该公司的买入评级。根据MarketBeat的数据，该公司目前的平均评级为持有，平均目标价为547.62美元。
Genmab A/S Stock Up 0.6 %
Genmab A/S股票上涨0.6%
Genmab A/S (NASDAQ:GMAB – Get Rating) last released its quarterly earnings data on Wednesday, August 10th. The company reported $0.41 earnings per share for the quarter, topping the consensus estimate of $0.21 by $0.20. The firm had revenue of $452.86 million for the quarter, compared to analyst estimates of $435.40 million. Genmab A/S had a net margin of 38.42% and a return on equity of 17.12%. Research analysts anticipate that Genmab A/S will post 1.02 earnings per share for the current year.
Genmab A/S(纳斯达克代码：GMAB-GET Rating)最近一次发布季度收益数据是在8月10日星期三。该公司公布本季度每股收益为0.41美元，比普遍预期的0.21美元高出0.20美元。该公司本季度营收为4.5286亿美元，而分析师预期为4.354亿美元。Genmab A/S的净利润率为38.42%，股本回报率为17.12%。研究分析师预计，Genmab A/S本年度每股收益将达到1.02美元。
Genmab A/S Company Profile
Genmab A/S公司简介
(Get Rating)
(获取评级)
Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; ofatumurnab, a human monoclonal antibody to treat chronic lymphocytic leukemia (CLL) and multiple sclerosis; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.
Genmab A/S主要在丹麦开发用于治疗癌症和其他疾病的抗体疗法。该公司销售用于治疗多发性骨髓瘤(MM)患者的人类单抗DARZALEX；用于治疗甲状腺眼病的teprotomumab；用于治疗慢性淋巴细胞白血病(CLL)和多发性硬化症的人类单抗Ofatumurnab；以及用于晚期或转移性胃癌、食道癌和非小细胞肺癌的Amivantamab。
Featured Stories
专题报道
- Get a free copy of the StockNews.com research report on Genmab A/S (GMAB)
- EV Battery Maker Freyr Set For Major Global Expansion
- MarketBeat: Week in Review 9/26 – 9/30
- This Is A Memorable Time To Buy Into Micron Technology
- Thor Industries Hammers Out A Bottom
- Declining Profits Challenge the CarMax Value Proposition
- 免费获取StockNews.com关于Genmab A/S(GMAB)的研究报告
- 电动汽车电池制造商Freyr将在全球大举扩张
- MarketBeat：回顾一周9/26-9/30
- 这是买入美光科技的难忘时刻
- 雷神工业走出谷底
- 利润下降对CarMax价值主张的挑战
Want to see what other hedge funds are holding GMAB? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Genmab A/S (NASDAQ:GMAB – Get Rating).
想看看还有哪些对冲基金持有GMAB吗？访问HoldingsChannel.com获取Genmab A/S(纳斯达克代码：GMAB-GET Rating)的最新13F备案文件和内幕交易信息。
Receive News & Ratings for Genmab A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genmab A/S and related companies with MarketBeat.com's FREE daily email newsletter.
接受Genmab A/S日报的新闻和评级-在下面输入您的电子邮件地址，通过MarketBeat.com的免费每日电子邮件时事通讯接收对Genmab A/S和相关公司的最新新闻和分析师评级的每日简要摘要。